Paysign’s Vice President of Patient Affordability, Logan Melchione, says clients are consistently frustrated by the dual burden of diversion and fraud on their programmes.
Both problems drain copay assistance programmes of critical funding, leaving fewer resources available to reach the patients who need financial support most.
Melchione describes the core challenge as teams lacking a quick, reliable way to quantify either problem and respond to it in a meaningful timeframe.
ClaimGuardRx, developed by Paysign, is designed to address both diversion and fraud simultaneously through a single unified platform.
The tool uses a conversational interface, meaning any member of an account team can pose questions directly and receive answers within seconds.
Those answers come complete with supporting data, removing the need for specialised analytical skills or lengthy reporting processes to extract actionable insight.
The speed and accessibility of the interface is precisely why account teams have come to regard ClaimGuardRx as what Melchione calls their smartest teammate on complex programme management challenges.
Copay assistance programmes have long been vulnerable to abuse, with diversion and fraud collectively redirecting funds away from legitimate patients and toward bad actors.
When programmes run healthier and leaner, more of the available copay assistance dollars ultimately reach the patients those programmes were designed to serve.
Paysign positions ClaimGuardRx as a practical operational tool rather than a back-office analytics product, putting real-time intelligence directly into the hands of frontline account teams.
The platform reflects a broader industry shift toward embedding data capability within everyday workflows rather than relying on separate reporting teams or delayed analysis cycles.
For pharmaceutical manufacturers running patient affordability programmes, the ability to detect and respond to fraud quickly has direct implications for both programme integrity and patient outcomes.
Melchione’s comments suggest that client demand for faster, more intuitive compliance and fraud tools is growing as programmes scale and the financial stakes increase.